[go: up one dir, main page]

CL2017001115A1 - Stable formulation of protein in solution that contains a high concentration of an anti-vegf antibody. - Google Patents

Stable formulation of protein in solution that contains a high concentration of an anti-vegf antibody.

Info

Publication number
CL2017001115A1
CL2017001115A1 CL2017001115A CL2017001115A CL2017001115A1 CL 2017001115 A1 CL2017001115 A1 CL 2017001115A1 CL 2017001115 A CL2017001115 A CL 2017001115A CL 2017001115 A CL2017001115 A CL 2017001115A CL 2017001115 A1 CL2017001115 A1 CL 2017001115A1
Authority
CL
Chile
Prior art keywords
high concentration
protein
solution
antibody
vegf antibody
Prior art date
Application number
CL2017001115A
Other languages
Spanish (es)
Inventor
Laman Alani
Huixiang Zhang
Charles Boring
Alok Kulshreshtha
Yuhong Zeng
Li Wan
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54697654&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017001115(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2017001115A1 publication Critical patent/CL2017001115A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
    • A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
    • A61B3/12—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN PROPORCIONA ANTICUERPOS ANTI-VEGF FORMULADOS COMO COMPOSICIONES FARMACÉUTICAS ACUOSAS DE ALTA CONCENTRACIÓN, ADECUADAS PARA INYECCIÓN, PREFERIBLEMENTE, UNA INYECCIÓN INTRAVITREAL. LAS COMPOSICIONES FARMACÉUTICAS ACUOSAS SON ÚTILES PARA LA ENTREGA DE UNA ALTA CONCENTRACIÓN DEL INGREDIENTE ACTIVO ANTICUERPO A UN PACIENTE SIN NIVELES ALTOS DE AGREGACIÓN DE ANTICUERPO Y SIN NIVELES ALTOS DE MATERIAL PARTICULADO SUBVISIBLE. UNA COMPOSICIÓN FARMACÉUTICA DE LA INVENCIÓN QUE COMPRENDE UN ANTICUERPO QUE TIENE UNA CONCENTRACIÓN DE AL MENOS 50 MG/MI. UNA COMPOSICIÓN FARMACÉUTICA ACUOSA DE LA INVENCIÓN QUE INCLUYE UN AZÚCAR, UN AGENTE REGULADOR DE PH Y UN SURFACTANTE.</p><p> THIS INVENTION PROVIDES ANTI-VEGF ANTIBODIES FORMULATED AS HIGH CONCENTRATION WATERPROOF COMPOSITIONS, SUITABLE FOR INJECTION, PREFERIBLY, AN INTRAVITREAL INJECTION. THE PASSIVE PHARMACEUTICAL COMPOSITIONS ARE USEFUL FOR THE DELIVERY OF A HIGH CONCENTRATION OF ANTIBODY ACTIVE INGREDIENT TO A PATIENT WITHOUT HIGH LEVELS OF ANTIBODY AGGREGATION AND WITHOUT HIGH LEVELS OF SUBVISIBLE PARTICULATE MATERIAL. A PHARMACEUTICAL COMPOSITION OF THE INVENTION THAT INCLUDES AN ANTIBODY THAT HAS A CONCENTRATION OF AT LEAST 50 MG / MI. A WATERPROOF PHARMACEUTICAL COMPOSITION OF THE INVENTION THAT INCLUDES A SUGAR, A PH REGULATING AGENT AND A SURFACTANT. </p>

CL2017001115A 2014-11-07 2017-05-05 Stable formulation of protein in solution that contains a high concentration of an anti-vegf antibody. CL2017001115A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462076770P 2014-11-07 2014-11-07
US201462088061P 2014-12-05 2014-12-05

Publications (1)

Publication Number Publication Date
CL2017001115A1 true CL2017001115A1 (en) 2018-01-26

Family

ID=54697654

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2017001117A CL2017001117A1 (en) 2014-11-07 2017-05-05 Methods to treat eye diseases.
CL2017001115A CL2017001115A1 (en) 2014-11-07 2017-05-05 Stable formulation of protein in solution that contains a high concentration of an anti-vegf antibody.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2017001117A CL2017001117A1 (en) 2014-11-07 2017-05-05 Methods to treat eye diseases.

Country Status (25)

Country Link
US (5) US10035850B2 (en)
EP (3) EP3215123A1 (en)
JP (6) JP6753848B2 (en)
KR (4) KR102724014B1 (en)
CN (4) CN107635580A (en)
AU (6) AU2015342815B2 (en)
BR (2) BR112017008093A2 (en)
CA (1) CA2966646A1 (en)
CL (2) CL2017001117A1 (en)
CO (1) CO2017004596A2 (en)
EA (1) EA201790989A1 (en)
EC (1) ECSP17034829A (en)
ES (1) ES3051145T3 (en)
GT (1) GT201700096A (en)
IL (5) IL251642B (en)
MX (3) MX383808B (en)
MY (2) MY193913A (en)
NZ (1) NZ730821A (en)
PE (1) PE20170780A1 (en)
PH (3) PH12021550147A1 (en)
RU (1) RU2722643C2 (en)
SG (3) SG11201702954XA (en)
TN (1) TN2017000128A1 (en)
TW (4) TWI705827B (en)
WO (2) WO2016073915A1 (en)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ571300A (en) 2006-04-07 2011-12-22 Warner Chilcott Co Llc Antibodies that bind human protein tyrosine phosphatase beta (HPTPBeta) and uses thereof
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
WO2009155723A2 (en) 2008-06-25 2009-12-30 Esbatech, An Alcon Biomedical Research Unit Llc STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα
ES2677003T3 (en) 2008-06-25 2018-07-27 Esbatech, An Alcon Biomedical Research Unit Llc Humanization of rabbit antibodies using a universal antibody framework
SG10201505672TA (en) 2009-07-06 2015-09-29 Aerpio Therapeutics Inc Compounds, compositions, and methods for preventing metastasis of cancer cells
SG191334A1 (en) 2011-01-13 2013-08-30 Regeneron Pharma Use of a vegf antagonist to treat angiogenic eye disorders
CA2850830A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
CN106456614A (en) 2014-03-14 2017-02-22 爱尔皮奥治疗有限公司 HPTP‑β inhibitors
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
TWI705827B (en) 2014-11-07 2020-10-01 瑞士商諾華公司 Methods for treating ocular diseases
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
EP3250596A1 (en) 2015-01-28 2017-12-06 Pfizer Inc Stable aqueous anti- vascular endothelial growth factor (vegf) antibody formulation
EP3352856B1 (en) 2015-09-23 2021-08-18 Aerpio Pharmaceuticals, Inc. Activators of tie-2 for use in treating intraocular pressure
UA126373C2 (en) 2015-12-04 2022-09-28 Новартіс Аг COMPOSITION AND METHOD FOR IMMUNO-ONCOLOGY
JP7088454B2 (en) 2015-12-30 2022-06-21 コディアック サイエンシーズ インコーポレイテッド Antibodies and antibody complexes
SG11201900464TA (en) 2016-07-20 2019-02-27 Aerpio Therapeutics Inc HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
AU2017324983B2 (en) * 2016-09-07 2025-03-20 Saksin Lifesciences Pvt Ltd Synthetic antibodies against VEGF and their uses
WO2018063963A1 (en) 2016-09-28 2018-04-05 Board Of Regents, The University Of Texas System Antibody and protein therapeutic formulations and uses thereof
TWI780082B (en) 2016-11-18 2022-10-11 日商安斯泰來製藥股份有限公司 Novel anti-human MUC1 antibody Fab fragment
WO2018175636A2 (en) 2017-03-22 2018-09-27 Novartis Ag Compositions and methods for immunooncology
JOP20190245A1 (en) 2017-04-20 2019-10-15 Novartis Ag Sustained release delivery systems comprising traceless linkers
CN109562166B (en) * 2017-04-28 2021-04-02 苏州思坦维生物技术股份有限公司 Medicinal composition for eyes and application thereof
TWI795415B (en) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 A novel anti-human CEACAM5 antibody Fab fragment
WO2019020777A1 (en) * 2017-07-26 2019-01-31 Formycon Ag Liquid formulation of a vegf antagonist
CN111315213B (en) 2017-10-06 2023-09-12 普罗塞纳生物科学有限公司 anti-transthyretin antibodies
WO2019071206A1 (en) 2017-10-06 2019-04-11 Prothena Biosciences Limited Methods of detecting transthyretin
CN111433223B (en) 2017-11-29 2024-08-27 诺和诺德A/S（股份有限公司） Lyophilized preparation of anti-transthyretin monoclonal antibody
MX2020005166A (en) 2017-11-30 2020-09-03 Regeneron Pharma Use of a vegf antagonist to treat angiogenic eye disorders.
EP4495136A3 (en) 2018-01-26 2025-04-23 The Regents of the University of California Methods and compositions for treatment of angiogenic disorders using anti-vegf agents
CN111699004A (en) * 2018-02-06 2020-09-22 豪夫迈·罗氏有限公司 Treatment of ophthalmic disorders
JP2021514656A (en) 2018-03-02 2021-06-17 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． IL-6 antibody and its fusion constructs and conjugates
KR20200131839A (en) * 2018-03-16 2020-11-24 노파르티스 아게 Eye disease treatment method
CN112004827A (en) * 2018-03-23 2020-11-27 艾伯维德国有限责任两合公司 Stable aqueous anti-TAU antibody formulations
EP3775267A4 (en) * 2018-04-10 2022-05-18 Askgene Pharma, Inc. NEW DUAL ANTAGONISTS OF VEGF AND ANGIOPOIETIN 2
LT4364724T (en) 2018-05-10 2026-01-12 Regeneron Pharmaceuticals, Inc. High concentration vegf receptor fusion protein containing formulations
US12202908B2 (en) 2018-05-17 2025-01-21 Astellas Pharma Inc. Complex having anti-human MUC1 antibody Fab fragment, peptide linker and/or ligand
CN120058958A (en) * 2018-09-24 2025-05-30 视点制药公司 Multispecific antibodies targeting HPTP-beta (VE-PTP) and VEGF
AR116566A1 (en) 2018-10-03 2021-05-19 Novartis Ag SUSTAINED ADMINISTRATION OF ANGIOPOYETIN-SIMILAR POLIPEPTIDES 3
JP7374544B2 (en) 2018-10-10 2023-11-07 アステラス製薬株式会社 Pharmaceutical composition comprising a labeling moiety-anti-human antibody Fab fragment complex
MA54052A (en) 2018-10-29 2022-02-09 Hoffmann La Roche ANTIBODY FORMULATION
CA3119179A1 (en) 2018-11-07 2020-05-14 Applied Molecular Transport Inc. Cholix-derived carriers for oral delivery of heterologous payload
JP7089121B2 (en) * 2018-12-18 2022-06-21 ノバルティス アーゲー Protein solution preparation containing high concentration of anti-VEGF antibody
CR20210435A (en) 2019-02-18 2021-09-20 Lilly Co Eli Therapeutic antibody formulation
TWI862583B (en) 2019-04-26 2024-11-21 美商愛德維仁生物科技公司 Variant aav capsids for intravitreal delivery
EP3962482A4 (en) 2019-04-29 2023-01-11 EyePoint Pharmaceuticals, Inc. TIE-2 ACTIVATORS TARGETING THE SCHLEMM CHANNEL
PH12022550330A1 (en) 2019-08-16 2023-02-06 Applied Molecular Transport Inc Compositions, formulations, and interleukin production and purification
EP4041312A4 (en) * 2019-10-10 2023-12-20 Kodiak Sciences Inc. METHODS OF TREATING AN EYE DISORDER
JP2023502501A (en) 2019-11-25 2023-01-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Long-acting VEGF inhibitors for intraocular angiogenesis
CN111217834B (en) * 2020-02-21 2021-10-26 维眸生物科技（上海）有限公司 Nitroxide derivatives of ROCK kinase inhibitors
MX2022010951A (en) * 2020-03-04 2022-10-07 Shanghai Henlius Biotech Inc Pharmaceutical formulation comprising bevacizumab.
CN113698478B (en) * 2020-05-21 2025-11-18 迈威(上海)生物科技股份有限公司 Anti-α-hemolysin antibodies and their stabilizing agents
KR20220001106A (en) 2020-06-29 2022-01-05 (주)메디톡스 High concentration anti-VEGF antibody formulation and anti-VEGF antibody for use in the same
PE20231093A1 (en) 2020-07-16 2023-07-18 Novartis Ag ANTI-BETACELLULIN ANTIBODIES, FRAGMENTS THEREOF, AND MULTISPECIFIC BINDING MOLECULES
JP2024519629A (en) * 2021-05-17 2024-05-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Long-term high-dose VEGF antagonist regimens for the treatment of neovascular eye diseases - Patents.com
CN113940997B (en) * 2021-12-21 2022-04-08 迈威(上海)生物科技股份有限公司 Stable preparation of bispecific antibody
WO2024056058A1 (en) * 2022-09-16 2024-03-21 齐鲁制药有限公司 Stable high-concentration self-buffering pharmaceutical composition
WO2025231345A1 (en) * 2024-05-03 2025-11-06 Therini Bio, Inc. Doses of antibodies which bind human fibrin yc or fibrinogen yc domain for ocular diseases

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JO3000B1 (en) * 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
HRP20120902T1 (en) * 2004-10-21 2012-12-31 Genentech, Inc. Method for treating intraocular neovascular diseases
WO2007011873A2 (en) * 2005-07-15 2007-01-25 Genentech, Inc. Method for treating intraocular neovascular diseases
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
DK2364691T3 (en) 2006-06-16 2013-07-01 Regeneron Pharma VEGF antagonist formulations that can be used for intravitreal administration
PE20090329A1 (en) 2007-05-30 2009-03-27 Abbott Lab HUMANIZED ANTIBODIES AGAINST GLOBULOMER AB (20-42) AND ITS USES
TWI468417B (en) 2007-11-30 2015-01-11 Genentech Inc Anti-vegf antibodies
PE20091174A1 (en) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd LIQUID FORMULATION WITH HIGH CONCENTRATION OF ANTIBODY CONTENT
ES2677003T3 (en) 2008-06-25 2018-07-27 Esbatech, An Alcon Biomedical Research Unit Llc Humanization of rabbit antibodies using a universal antibody framework
KR102013220B1 (en) * 2008-06-25 2019-08-23 에스바테크 - 어 노바티스 컴파니 엘엘씨 Stable and soluble antibodies inhibiting vegf
WO2009155723A2 (en) 2008-06-25 2009-12-30 Esbatech, An Alcon Biomedical Research Unit Llc STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα
MX344076B (en) 2008-06-30 2016-12-05 Esbatech Alcon Biomed Res Unit Functionalized polypeptides.
ES2765657T3 (en) 2009-12-21 2020-06-10 Hoffmann La Roche Pharmaceutical formulation of bevacizumab
WO2012076670A2 (en) 2010-12-10 2012-06-14 Novartis Ag Antibody formulation
SG191334A1 (en) * 2011-01-13 2013-08-30 Regeneron Pharma Use of a vegf antagonist to treat angiogenic eye disorders
RU2013155695A (en) * 2011-06-30 2015-08-10 Дженентек, Инк. ANTIBODIES AGAINST C-MET
EP3431495A1 (en) * 2011-10-20 2019-01-23 ESBATech - a Novartis Company LLC Stable multiple antigen-binding antibody
MX373352B (en) 2012-05-03 2020-03-27 Kala Pharmaceuticals Inc PHARMACEUTICAL NANOPARTICLES THAT SHOW IMPROVEMENT OF MUCOSAL TRANSPORT.
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
JOP20200175A1 (en) 2012-07-03 2017-06-16 Novartis Ag Syringe
UA117466C2 (en) * 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. STABLE COMPOSITION IN THE VIEW OF AN ANTIBODY ANTIBODY TO IL-23p19
CN105209069B (en) 2013-03-13 2019-08-23 豪夫迈·罗氏有限公司 Antibody formulation
WO2015086830A1 (en) * 2013-12-13 2015-06-18 Delenex Therapeutics Ag Skin penetrating polypeptides
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
CA2952822A1 (en) * 2014-06-17 2015-12-23 Clearside Biomedical, Inc. Methods and devices for treating posterior ocular disorders
TWI705827B (en) 2014-11-07 2020-10-01 瑞士商諾華公司 Methods for treating ocular diseases
US20160144025A1 (en) 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
KR20200131839A (en) 2018-03-16 2020-11-24 노파르티스 아게 Eye disease treatment method
JP7089121B2 (en) 2018-12-18 2022-06-21 ノバルティス アーゲー Protein solution preparation containing high concentration of anti-VEGF antibody

Also Published As

Publication number Publication date
MX2017005874A (en) 2017-06-26
AU2015342815A1 (en) 2017-05-11
US10035850B2 (en) 2018-07-31
AU2020244614B2 (en) 2023-06-01
US12371481B2 (en) 2025-07-29
WO2016073915A1 (en) 2016-05-12
WO2016073918A1 (en) 2016-05-12
MY183807A (en) 2021-03-16
CN106999581A (en) 2017-08-01
KR20240161204A (en) 2024-11-12
US20180298092A1 (en) 2018-10-18
AU2015342818B2 (en) 2019-01-03
GT201700096A (en) 2019-10-10
IL283561A (en) 2021-07-29
EP3215122A1 (en) 2017-09-13
CO2017004596A2 (en) 2017-08-31
AU2018274882B2 (en) 2020-07-09
CN107635580A (en) 2018-01-26
EP3215122C0 (en) 2025-08-13
AU2015342815B2 (en) 2018-12-13
AU2015342818A1 (en) 2017-05-11
BR112017008093A2 (en) 2018-03-13
AU2018278870B2 (en) 2020-05-28
AU2018278870A1 (en) 2019-01-03
AU2020244614A1 (en) 2020-11-05
EP4684797A2 (en) 2026-01-28
US20160340420A1 (en) 2016-11-24
IL280087A (en) 2021-03-01
TWI761959B (en) 2022-04-21
IL251642A0 (en) 2017-06-29
SG10201913565RA (en) 2020-02-27
KR20170076781A (en) 2017-07-04
PE20170780A1 (en) 2017-07-04
PH12017500843A1 (en) 2017-10-30
US11098110B2 (en) 2021-08-24
PH12021550147A1 (en) 2023-01-23
CN120938921A (en) 2025-11-14
IL265497A (en) 2019-05-30
PH12017500844A1 (en) 2017-10-30
KR102588846B1 (en) 2023-10-16
KR20170082526A (en) 2017-07-14
CL2017001117A1 (en) 2018-01-26
TW201625221A (en) 2016-07-16
US20160130337A1 (en) 2016-05-12
IL251642B (en) 2021-02-28
AU2018274882A1 (en) 2018-12-20
TWI705827B (en) 2020-10-01
RU2017119647A (en) 2018-12-07
TW202146049A (en) 2021-12-16
CA2966646A1 (en) 2016-05-12
AU2020220210B2 (en) 2022-01-20
IL283561B (en) 2022-01-01
RU2020114917A (en) 2020-05-22
RU2020114917A3 (en) 2022-01-17
JP2020079242A (en) 2020-05-28
IL251696A0 (en) 2017-06-29
EP3215122B1 (en) 2025-08-13
ES3051145T3 (en) 2025-12-26
JP6753848B2 (en) 2020-09-09
JP2017538674A (en) 2017-12-28
TWI738632B (en) 2021-09-11
IL265497B (en) 2021-06-30
JP2017534638A (en) 2017-11-24
JP6667519B2 (en) 2020-03-18
MY193913A (en) 2022-11-01
MX2017005875A (en) 2017-06-26
MX383808B (en) 2025-03-14
KR102724014B1 (en) 2024-10-31
SG11201702954XA (en) 2017-05-30
CN114081951A (en) 2022-02-25
CA2966758A1 (en) 2016-05-12
MX383399B (en) 2025-03-13
BR112017008660A2 (en) 2017-12-26
US20200270336A1 (en) 2020-08-27
TW202103735A (en) 2021-02-01
ECSP17034829A (en) 2019-02-28
TWI806150B (en) 2023-06-21
JP2025004075A (en) 2025-01-14
KR20230066649A (en) 2023-05-16
US12049495B2 (en) 2024-07-30
RU2017119647A3 (en) 2019-05-29
JP2022141923A (en) 2022-09-29
RU2722643C2 (en) 2020-06-02
TN2017000128A1 (en) 2018-10-19
PH12017500844B1 (en) 2021-05-05
JP2020193212A (en) 2020-12-03
NZ730821A (en) 2019-11-29
IL280087B (en) 2022-02-01
MX2021006768A (en) 2021-07-15
EA201790989A1 (en) 2017-09-29
EP3215123A1 (en) 2017-09-13
SG11201702909QA (en) 2017-05-30
US10689438B2 (en) 2020-06-23
JP7080263B2 (en) 2022-06-03
TW201625306A (en) 2016-07-16
AU2020220210A1 (en) 2020-10-01
US20210340242A1 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
CL2017001115A1 (en) Stable formulation of protein in solution that contains a high concentration of an anti-vegf antibody.
CY1122181T1 (en) PHARMACEUTICAL FORM OF ANTIBODY
AR111455A1 (en) STABLE FORMULATION OF ANTIBODY
MX2017010400A (en) Stable liquid formulation for monoclonal antibodies.
PH12017501774A1 (en) Compositions comprising a combination of an anti-pd-1 antibody and another antibody
BR112016026811A2 (en) antibody formulation
CO7111300A2 (en) Antibody formulation
CL2018003178A1 (en) Pharmaceutical composition
EA201991447A1 (en) VISCOSITY REDUCTION OF PHARMACEUTICAL COMPOSITIONS
CL2021001587A1 (en) Protein solution formulation containing a high concentration of an anti-vegf antibody
AR091530A1 (en) PHARMACEUTICAL FORMULATION LIQUID OF AN ANTIBODY AND ACETATE
MX2019014666A (en) Pharmaceutical composition comprising c-met antibody-drug conjugate and use thereof.
AR130115A2 (en) STABLE PROTEIN SOLUTION FORMULATION CONTAINING A HIGH CONCENTRATION OF AN ANTI-VEGF ANTIBODY
AR102572A1 (en) FORMULATION OF STABLE PROTEIN SOLUTION CONTAINING HIGH CONCENTRATION OF AN ANTI-VEGF ANTIBODY